Weekly growth hormone injections improve treatment satisfaction in patients with GHD
Somapacitan, a once-weekly growth hormone injection, significantly improves treatment convenience for adults with growth hormone deficiency (GHD) compared to daily GH injections, while maintaining similar efficacy in key health markers, according to a study.
A recent 24-week, randomized study assessed various health markers, including insulin-like growth factor 1 (IGF-1) levels, glucose and lipid profiles, body composition, and bone mineral density (BMD) of 29 adults who had been on daily GH therapy for at least 5 years and randomized to receive either somapacitan or daily GH.
The primary finding was a notable improvement in convenience scores on the Treatment Satisfaction Questionnaire for Medication-9, favoring somapacitan (P = 0.004).
Health outcomes, including IGF-1 levels, metabolic parameters, and body composition, remained stable between both treatment groups. However, a slight but significant decrease in lumbar spine BMD was observed with somapacitan (P = 0.011), which researchers suggest may reflect an expected initial bone remodeling response.
Reference
Jensterle M, Herman R, Klinc A, et al. Efficacy of somapacitan in treatment-fatigue adult patients with growth hormone deficiency previously treated with once-daily growth hormone injections: a 24-week randomized active-controlled trial. Endocr Pract. 2025;S1530-891X(25)00073-4. doi: 10.1016/j.eprac.2025.03.005. Epub ahead of print. PMID: 40107502.
